Shifts in subsets of CD8 T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control studyReportar como inadecuado




Shifts in subsets of CD8 T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 15:1016

First Online: 28 December 2015Received: 19 October 2014Accepted: 15 December 2015DOI: 10.1186-s12885-015-2013-3

Cite this article as: Onyema, O.O., Decoster, L., Njemini, R. et al. BMC Cancer 2015 15: 1016. doi:10.1186-s12885-015-2013-3

Abstract

BackgroundShifts in CD8+ T-cell subsets that are hallmarks of immunosenescence are observed in ageing and in conditions of chronic immune stimulation. Presently, there is limited documentation of such changes in lung cancer and other malignancies affecting the lungs.

MethodsChanges in CD8+ T-cell subsets, based on the expression of CD28 and CD57, were analysed in patients with various forms of cancer affecting the lungs, undergoing chemotherapy and in a control group over six months, using multi-colour flow cytometry.

ResultsThe differences between patients and controls, and the changes in the frequency of CD8+ T-cell subpopulations among lung cancer patients corresponded to those seen in immunosenescence: lower CD8-CD8+ ratio, lower proportions of CD28+CD57- cells consisting of naïve and central memory cells, and higher proportions of senescent-enriched CD28-CD57+ cells among the lung cancer patients, with the stage IV lung cancer patients showing the most pronounced changes. Also observed was a tendency of chemotherapy to induce the formation of CD28+CD57+ cells, which, in line with the capacity of chemotherapy to induce the formation of senescent cells, might provide more evidence supporting CD28+CD57+ cells as senescent cells.

ConclusionImmunosenescence was present before the start of the treatment; it appeared to be pronounced in patients with advanced cases of malignancies affecting the lungs, and might not be averted by chemotherapy.

KeywordsCellular senescence Immunosenescence Lung cancer Chemotherapy Immune risk profile Abbreviations7-AAD7-amino actinomycin-D

BSA-PBSbuffering solution

CDCisplatin and docetaxel

CDKCyclin dependent kinase

CECisplatin and etoposide

CGCisplatin and gemcitabine

CMVCytomegalovirus

CPCisplatin and pemetrexed

CVCisplatin and vinorelbine

FITCFluorescein isothiocyanate

HIVHuman immunodeficiency virus

IRPImmune risk profile

MMMalignant mesothelioma

NNumber

NSCCNon squamous cell carcinoma

NSCLCNon-small cell lung cancer

PBLPeripheral blood leukocytes

PER-Phycoerythrin

Q1Lower quartile

Q3Upper quartile

RRadiotherapy

SCCSquamous cell carcinoma of the lung

SCLCSmall cell lung cancer

SIPSStress induced premature senescence

T0Baseline, before treatment

T1After 1 month

T3After 3 months

T6After six months

Download fulltext PDF



Autor: Oscar Okwudiri Onyema - Lore Decoster - Rose Njemini - Louis Nuvagah Forti - Ivan Bautmans - Marc De Waele - Tony Mets

Fuente: https://link.springer.com/







Documentos relacionados